Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Neurology

Prognosis and the Road to Recovery from AIDP

At a Glance

Recovery from AIDP is a gradual process, but the long-term prognosis is generally very positive. Rebuilding nerve insulation takes time, but with physical and occupational therapy, the vast majority of patients eventually regain the ability to walk independently and return to daily activities.

Recovery from Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is often described by patients as a marathon, not a sprint. While the initial “attack” phase is over within a few weeks, the process of rebuilding the myelin insulation and regaining strength takes time [1][2].

Predicting Your Recovery

Doctors use specific “calculators” to help set expectations for your recovery. These tools look at your age, your strength at the beginning, and whether you had a preceding infection [3][4].

  • mEGRIS (Respiratory Risk): This score helps doctors predict if a patient might need help breathing with a ventilator. It is used during the first few days in the hospital to ensure the right level of care is available before a crisis occurs [5][6].
  • mEGOS (Walking Recovery): The modified Erasmus GBS Outcome Score is the gold standard for predicting functional recovery [7]. By looking at your strength at the one-week mark, doctors can estimate the likelihood that you will be walking independently at 6 months and 1 year [3][8].
  • The Good News: AIDP generally has a more favorable long-term prognosis than the rarer axonal forms of GBS. The vast majority of patients with AIDP eventually regain the ability to walk independently [9][10].

The Role of Rehabilitation

Rehabilitation is the most critical part of your recovery after the initial medical treatment is finished.

  • Physiotherapy: Starting physical therapy as soon as it is medically safe (even while in the hospital) is associated with faster recovery, shorter hospital stays, and better overall quality of life [11][12].
  • Occupational Therapy: This focuses on fine motor skills, like buttoning a shirt or using a keyboard, which can be affected if there is residual nerve damage in the hands [13].
  • Behavioral Therapy: Many patients experience a significant psychological toll, including anxiety, depression, or even PTSD from the experience of sudden paralysis [14]. Specialized therapy can help manage these emotions and improve your functional independence [14].

Common Long-Term Challenges (Survivorship)

Even after you are back on your feet, you may face “invisible” symptoms that require ongoing management.

  • Fatigue: This is one of the most common long-term complaints among GBS survivors. It is not just “being tired”; it is a profound sense of exhaustion that can persist even when muscle strength has returned.
  • Neuropathic Pain: As nerves heal, they can send “misfire” signals to the brain, causing sensations of burning, tingling, or electric shocks [15][16]. Do not settle for over-the-counter pain relievers if you are suffering; this is often managed with specific nerve-pain medications, such as gabapentin or pregabalin, which your doctor can prescribe [17].
  • Pacing: Learning to “pace” your activities is vital. Doing too much too soon can lead to a temporary increase in fatigue or pain, making it feel like you are having a relapse when you are actually just overexerting healing nerves.

Summary of Recovery Timeline

Phase Focus Key Milestone
Weeks 1–4 Acute Treatment Reaching the “nadir” (the peak of symptoms) [1].
Weeks 4–12 Early Rehab Regaining core strength; transitioning from bed to chair [11].
Months 3–12 Functional Recovery Walking with or without assistance; return to daily tasks [3].
Year 1+ Survivorship Managing fatigue, fine motor skills, and emotional health [13][14].

The journey is long, but most patients continue to see improvements in their strength and function for up to two years or more after the initial diagnosis [18]. Celebrate the small victories along the way.

(Return to the Home Page)

Common questions in this guide

How long does it take to recover from AIDP?
Recovery from AIDP typically happens in stages over several months to years. While acute symptoms peak within a few weeks, functional recovery like walking often takes three to twelve months, and gradual improvements can continue for two years or more.
What is the mEGOS score for AIDP?
The modified Erasmus GBS Outcome Score (mEGOS) is a tool doctors use to predict your functional recovery. By assessing your strength one week into the illness, it helps estimate the likelihood that you will be able to walk independently at six months and one year.
Will I be able to walk again after having AIDP?
Yes, the vast majority of patients with AIDP eventually regain the ability to walk independently. AIDP generally has a more favorable long-term prognosis compared to other rarer forms of the condition.
Why am I so exhausted during my AIDP recovery?
Profound fatigue is one of the most common long-term challenges for survivors. Healing nerves require significant energy, and overexerting yourself can temporarily worsen fatigue, making careful pacing of your daily activities essential.
How is nerve pain treated during AIDP recovery?
As damaged nerves heal, they can misfire and send painful burning, tingling, or electric shock signals. This neuropathic pain is often treated with specific prescription nerve-pain medications like gabapentin or pregabalin, rather than standard over-the-counter pain relievers.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my mEGOS score at Day 7, and what does it suggest about my ability to walk in 6 months?
  2. 2.Can you recommend a physical therapist who has specific experience with GBS or peripheral nerve recovery?
  3. 3.I'm feeling very [tired/depressed/anxious] — is this a common part of the 'survivorship' phase of AIDP?
  4. 4.What medications (like gabapentin or pregabalin) can help manage the burning nerve pain I'm experiencing?
  5. 5.When is it safe for me to start aerobic exercise or return to work part-time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Clinical features and outcome of Guillain-Barre syndrome in Saudi Arabia: a multicenter, retrospective study.

    Alanazy MH, Bakry SS, Alqahtani A, et al.

    BMC neurology 2021; (21(1)):275 doi:10.1186/s12883-021-02314-5.

    PMID: 34253174
  2. 2

    Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease.

    Arsenijević M, Berisavac I, Mladenović B, et al.

    Irish journal of medical science 2021; (190(1)):357-361 doi:10.1007/s11845-020-02310-7.

    PMID: 32666503
  3. 3

    Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.

    Doets AY, Lingsma HF, Walgaard C, et al.

    Neurology 2022; (98(5)):e518-e532 doi:10.1212/WNL.0000000000013139.

    PMID: 34937789
  4. 4

    Diabetes mellitus may affect short-term outcome of Guillain-Barré syndrome.

    Peric S, Bozovic I, Bjelica B, et al.

    Journal of the peripheral nervous system : JPNS 2017; (22(2)):127-130 doi:10.1111/jns.12206.

    PMID: 28177572
  5. 5

    Utility of the "Modified Erasmus GBS Respiratory Insufficiency Score" in Axonal and Demyelinating Guillain-Barré Syndrome.

    Sekiguchi Y, Misawa S, Morooka M, et al.

    Journal of the peripheral nervous system : JPNS 2026; (31(1)):e70096 doi:10.1111/jns.70096.

    PMID: 41492176
  6. 6

    Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome.

    Luijten LWG, Doets AY, Arends S, et al.

    Journal of neurology, neurosurgery, and psychiatry 2023; (94(4)):300-308 doi:10.1136/jnnp-2022-329937.

    PMID: 36428088
  7. 7

    Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.

    Neurology 2024; (103(9)):e209968 doi:10.1212/WNL.0000000000209968.

    PMID: 39348619
  8. 8

    European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.

    van Doorn PA, Van den Bergh PYK, Hadden RDM, et al.

    European journal of neurology 2023; (30(12)):3646-3674 doi:10.1111/ene.16073.

    PMID: 37814552
  9. 9

    Clinical Outcome of Guillain-Barré Syndrome in 108 Children.

    Sen S, Kumar A, Roy B

    Indian pediatrics 2021; (58(9)):833-835.

    PMID: 33506807
  10. 10

    Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.

    Zhang G, Li Q, Zhang R, et al.

    PloS one 2015; (10(7)):e0133520 doi:10.1371/journal.pone.0133520.

    PMID: 26200903
  11. 11

    Augmented reality assisted physiotherapy rehabilitation in early phase of guillain barre syndrome (AIDP)-a case report.

    Shah R, Samal S

    BMC neurology 2026; (26(1)).

    PMID: 41629798
  12. 12

    Integrated treatment approach to Miller Fisher syndrome, a variant of Guillain-Barre syndrome - A case report.

    Yadav P, Vaishali Kuchewar , Bhusari N, Yadav T

    Journal of Ayurveda and integrative medicine 2025; (16(4)):101159 doi:10.1016/j.jaim.2025.101159.

    PMID: 40580907
  13. 13

    Fine Motor Outcomes in Children with Guillain-Barré Syndrome.

    Kumar A, Saini L, Gunasekaran PK, et al.

    Indian journal of pediatrics 2026; (93(3)):282-287 doi:10.1007/s12098-025-05891-2.

    PMID: 41417155
  14. 14

    A propensity score matched retrospective study of psychological and behavioral therapy impact on muscle function recovery in Guillain Barré Syndrome.

    Lu Z, Xie X, Rui Z, et al.

    Scientific reports 2025; (15(1)):31880 doi:10.1038/s41598-025-16482-8.

    PMID: 40883445
  15. 15

    Headache and Pain in Guillain-Barré Syndrome.

    Farmakidis C, Inan S, Milstein M, Herskovitz S

    Current pain and headache reports 2015; (19(8)):40 doi:10.1007/s11916-015-0508-x.

    PMID: 26122532
  16. 16

    Peripheral nerve-targeting and pain-promoting transcriptomic signatures in early Guillain-Barré syndrome.

    O'Brien JA, Lesnak JB, Sankaranarayanan I, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.09.24.678413.

    PMID: 41040175
  17. 17

    Pain in acute motor axonal neuropathy.

    Zhao F, Wang J, Zhang J, et al.

    Muscle & nerve 2021; (64(6)):739-743 doi:10.1002/mus.27414.

    PMID: 34506042
  18. 18

    International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

    Jacobs BC, van den Berg B, Verboon C, et al.

    Journal of the peripheral nervous system : JPNS 2017; (22(2)):68-76 doi:10.1111/jns.12209.

    PMID: 28406555

This page provides educational information about AIDP recovery timelines and prognosis. Always consult your neurologist or physical therapist for a rehabilitation plan tailored to your specific recovery needs.

Get notified when new evidence is published on Acute inflammatory demyelinating polyradiculoneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.